Evanson J A, Himmelfarb J, Wingard R, Knights S, Shyr Y, Schulman G, Ikizler T A, Hakim R M
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.
Am J Kidney Dis. 1998 Nov;32(5):731-8. doi: 10.1016/s0272-6386(98)70127-1.
The current study was designed first to determine separately the prescribed and delivered dose of dialysis and, second, to determine what factors lead to failure to deliver the prescribed dose of dialysis in patients with acute renal failure (ARF). Forty patients, who collectively underwent 136 dialysis treatments, were studied prospectively at two institutions. The results showed that almost half the prescriptions (49%) were for a Kt/V less than 1.2 and, more importantly, nearly 70% of the treatments delivered a Kt/V less than 1.2, the minimally acceptable dose defined in the Dialysis Outcomes Quality Initiative (DOQI) guidelines for chronic hemodialysis (CHD) patients. Patient predialysis weight was the most important variable associated with a low prescribed and delivered dose of dialysis, as well as lack of delivery of the prescribed dose of dialysis. From the statistical model, it is estimated that for every 10-kg increase in predialysis weight, the chance of prescribing or delivering a Kt/V less than 1.2 increased 4.6- and 1.95-fold, respectively. The lower than prescribed blood flow achieved by the temporary catheters and patients not receiving anticoagulation were variables also associated with not receiving the prescribed Kt/V. It is concluded that patients with ARF are prescribed and receive a dose of dialysis that would be considered inadequate for CHD patients. Until the association between dose of dialysis and outcome is better defined, it would be prudent that both the dialysis prescription and the delivery of dialysis to patients with ARF should be performed with the same care and goals as that currently received by patients with end-stage renal disease (ESRD).
其一,分别确定急性肾衰竭(ARF)患者的透析处方剂量和实际给予剂量;其二,确定导致未能给予ARF患者规定透析剂量的因素。在两家机构对40例患者进行了前瞻性研究,这些患者共接受了136次透析治疗。结果显示,几乎一半的处方(49%)设定的Kt/V小于1.2,更重要的是,近70%的治疗所给予的Kt/V小于1.2,这是透析预后质量倡议(DOQI)慢性血液透析(CHD)患者指南中定义的最低可接受剂量。患者透析前体重是与低透析处方剂量、低实际给予剂量以及未能给予规定透析剂量相关的最重要变量。根据统计模型估计,透析前体重每增加10 kg,处方或给予Kt/V小于1.2的可能性分别增加4.6倍和1.95倍。临时导管导致的血流量低于规定值以及未接受抗凝治疗的患者也是与未达到规定Kt/V相关的变量。得出的结论是,ARF患者所接受的透析处方剂量和实际给予剂量对于CHD患者而言被认为是不足的。在透析剂量与预后之间的关联得到更好界定之前,谨慎的做法是,对ARF患者进行透析处方和透析治疗时,应给予与目前终末期肾病(ESRD)患者相同的关注并设定相同的目标。